Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Leonard Heffner"'
Autor:
Nicola Gökbuget, Hagop M. Kantarjian, Monika Brüggemann, Anthony S. Stein, Ralf C. Bargou, Hervé Dombret, Adele K. Fielding, Leonard Heffner, Françoise Rigal-Huguet, Mark Litzow, Susan O'Brien, Gerhard Zugmaier, Shan Gao, Dirk Nagorsen, Stephen J. Forman, Max S. Topp
Publikováno v:
Blood Advances, Vol 3, Iss 20, Pp 3033-3037 (2019)
Abstract: Minimal residual disease (MRD), where leukemic cell levels are lower than the morphologic detection threshold, is the most important prognostic factor for acute lymphoblastic leukemia (ALL) relapse during first-line chemotherapy treatment a
Externí odkaz:
https://doaj.org/article/512b167390dd4c51bc5396468525468a
Autor:
Anthony R. Mato, William G. Wierda, Matthew S. Davids, Bruce D. Cheson, Steven E. Coutre, Michael Choi, Richard R. Furman, Leonard Heffner, Paul M. Barr, Herbert Eradat, Sharanya M. Ford, Lang Zhou, Maria Verdugo, Rod A. Humerickhouse, Jalaja Potluri, John C. Byrd
Publikováno v:
Haematologica, Vol 104, Iss 11 (2019)
The utility of positron emission tomography-computed tomography (PET-CT) in distinguishing Richter’s transformation versus chronic lymphocytic leukemia (CLL) progression after ibrutinib and/or idelalisib was assessed in a post hoc analysis of a pha
Externí odkaz:
https://doaj.org/article/2eb9743dadf8446b8ea8d2185f71d8bf
Autor:
Leon Bernal-Mizrachi, Ajay K. Nooka, Leonard Heffner, Craig E. Cole, Ravi Vij, J Christine Ye, Craig C Hofmeister, John Rushton, Zhengjia Chen, Subir Goyal, Munevver Cinar, Sagar Lonial, Jonathan L. Kaufman
Publikováno v:
Blood. 138:2758-2758
Introduction: Proteasome inhibitors (PI) and immunomodulatory drugs have become the backbone of therapy for multiple myeloma (MM). The oral boron-containing selective and reversible proteasome inhibitor ixazomib has shown to induce deep and durable r
Autor:
Pranav Santapuram, Manali Rupji, Michael Graiser, Edmund Waller, Kristie Blum, Pamela Allen, Jean Koff, Leonard Heffner, Mary Lechowicz, Sagar Lonial, Jonathan Kaufman, Madhav Dhopadkar, Ajay Nooka, William Blum, Rebecca Klisovic, Nisha Joseph, Vikas Gupta, Amelia Langston, Jonathan Cohen
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S240
Autor:
Leon Bernal-Mizrachi, Ajay K Nooka, Leonard Heffner, Craig E. Cole, J Christine Ye, Ravi Vij, Craig C Hofmeister, John Rushton, Zhengjia Chen, Zhao Chang, Munevver Cinar, Daniel Auclair, Sagar Lonial, Jonathan L. Kaufman
Publikováno v:
Blood. 134:3188-3188
Introduction: Proteasome inhibitors (PI) and immunomodulatory drugs have become the backbone of therapy for multiple myeloma (MM). The oral boron-containing selective and reversible proteasome inhibitor ixazomib has shown to induce deep and durable r
Autor:
Steven P Treon, Christina K Tripsas, Leukothea Ioakimidis, Diane Warren, Christopher Patterson, Leonard Heffner, Herbert Eradat, Stephanie A. Gregory, Sheeba Thomas, Ranjana Advani, Rachid Baz, Ashraf Z. Badros, Jeffrey Matous, Kenneth C. Anderson, Irene M. Ghobrial
Publikováno v:
Blood. 118:2951-2951
Abstract 2951 Introduction: Everolimus (RAD001) is an inhibitor of MTORC1, a component of the Akt-MTOR pathway which regulates growth and survival of lymphoplasmacytic cells in Waldenstrom's Macroglobulinemia (WM). Everolimus also exhibits activity i
Autor:
Jonathan L. Kaufman, Jatin J Shah, Jacob P. Laubach, Leonard Heffner, Dixil Francis, R. Donald Harvey, Colleen Lewis, Mourad Tighiouart, Paul Richardson, Robert Z. Orlowski, Sagar Lonial
Publikováno v:
Blood. 116:3034-3034
Abstract 3034 Background: The combination of lenalidomide (R), bortezomib (V), and dexamethasone (D) (RVD) in newly diagnosed MM patients is well tolerated and associated with a very high overall response rate. The goal of the current trial is to imp